戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 opic tumors selectively using an activatable immunoconjugate.
2  in >95% of the (64)Cu being chelated by the immunoconjugate.
3 cted tumor, which synthesize and secrete the immunoconjugates.
4  cells and complement in the presence of the immunoconjugates.
5 ) to the activity of bivalent IgG-containing immunoconjugates.
6 und to the radiometal to create radiolabeled immunoconjugates.
7 ell death induced by the fusion peptides and immunoconjugates.
8  competitive binding assay demonstrates that immunoconjugate 2 binds to SKOV3 tumor cells comparably
9  thiol-maleimide chemistry, thereby yielding immunoconjugate 2.
10 Using fluorescence microendoscopy to monitor immunoconjugate activation and micrometastatic disease,
11  The results demonstrate that a mutated fVII immunoconjugate, administered separately or together wit
12                   For the next generation of immunoconjugates, advances in protein engineering will p
13        The in vitro results suggest that the immunoconjugates also could activate a specific cytolyti
14 icited by active immunization with a cocaine immunoconjugate and binds free cocaine with excellent sp
15 lanoma protein was immunoprecipitated by the immunoconjugates and analyzed by mass spectrometry, usin
16 o acid produces a chemical "handle" by which immunoconjugates and multimers can be engineered.
17                                              Immunoconjugates and multispecific antibodies are rapidl
18 in vitro FcgammaRI binding of deglycosylated immunoconjugates and significant decreases in the in viv
19 ells were conducted with the photosensitizer immunoconjugates and, for comparison, with free PPa.
20 rosine kinase inhibitors, ligand conjugates, immunoconjugates, and antisense oligonucleotides.
21 sine kinase inhibitors, synthetic retinoids, immunoconjugates, and immunosuppressive molecules with n
22 geted therapies using monoclonal antibodies, immunoconjugates, and immunotoxins.
23 icant barriers to penetration by antibodies, immunoconjugates, and other immunotoxins.
24 n prostate cancer, especially with anti-HER3 immunoconjugates, and targeting HER3 warrants clinical e
25  the development of a mouse B cell-depleting immunoconjugate (anti-CD22 monoclonal antibody [mAb] con
26 SMA(ext), thus targeting viable tumor, these immunoconjugates are better candidates for targeted radi
27          Our studies demonstrated that these immunoconjugates are effective both in vitro and in test
28                     The resulting boron-rich immunoconjugates are formed efficiently, are readily pur
29                               However, these immunoconjugates are highly prone to noncovalent, dimeri
30 s (QDs), where both the assemblies and their immunoconjugates are prepared by self-assembly.
31 ability, minimizing the toxicity of 90Y-DOTA immunoconjugates arising from loss of 90Y to bone.
32 receive up to eight monthly infusions of the immunoconjugate at 2 mg/m(2).
33                                  In summary, immunoconjugates based on lytic peptides are a promising
34 we synthesized an HER2-targeting trastuzumab immunoconjugate bearing a NIR-II aza-BODIPY fluorophore.
35             Gemtuzumab ozogamicin (GO) is an immunoconjugate between CD33 and calicheamicin that is i
36 er immunoconjugate, provided photosensitizer immunoconjugate binding was saturated.
37                The Fc effector domain of the immunoconjugates binds natural killer (NK) cells and als
38 ature, presumably mediated by the factor VII immunoconjugate bound to tissue factor on neovasculature
39 n chemotherapy strategies, radiotherapy, the immunoconjugate brentuximab, checkpoint inhibitors nivol
40                                          The immunoconjugate C242-DM1 was prepared by conjugating DM1
41 second-generation TF-targeting antibody-like immunoconjugate (called L-ICON) for preclinical treatmen
42                                      The new immunoconjugate, called EV20/Omomyc, was developed by li
43 ggest that ephB2 is an attractive target for immunoconjugate cancer therapy.
44 4 days after treatment with a single dose of immunoconjugate carrying 2.5 ng of Dox, LoVo and SW-480
45  refractory CD33(+) AML were treated with an immunoconjugate (CMA-676) consisting of humanized anti-C
46                                              Immunoconjugates composed of antibodies conjugated to ra
47 tion-incompetent adenoviral vectors encoding immunoconjugates composed of the Fc region of an IgG1 im
48          Antibody-drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal antibody teth
49                         The synthesis of the immunoconjugate consists of covalent attachment of the N
50                                          One immunoconjugate containing an antibody and a chemotherap
51                             Two antimelanoma immunoconjugates containing a human single-chain Fv (scF
52 a crenulata (KLH) were prepared as effective immunoconjugates containing a sensitive fluorescent repo
53 othelial cells and tumor cells, a factor VII immunoconjugate could be used for immunotherapy against
54 tive vaccination of mature rats with ghrelin immunoconjugates decreases feed efficiency, relative adi
55            Herein, we generated a bispecific immunoconjugate [denoted as Bs-F(ab)2] by linking two an
56 itro cytolysis assay was used to test for an immunoconjugate-dependent specific cytolytic response ag
57                                MLN2704 is an immunoconjugate designed to deliver the maytansinoid ant
58 N,N',N",N"'-tetraacetic acid) and the intact immunoconjugate DOTA-NR-LU-10 were labeled to high speci
59  experiments with 2IT-BAD-Lym-1 and a second immunoconjugate, DOTA-peptide-chimeric L6, with 248-492
60 that intratumoral delivery of the factor VII immunoconjugate, either alone or together with the singl
61            Phase I trials of a calicheamicin immunoconjugate for treatment of acute myeloid leukemia
62  of acute myeloid leukemia and a doxorubicin immunoconjugate for treatment of carcinoma have recently
63 luorophores for tracking and photosensitizer immunoconjugates for photoimmunotherapy.
64 men described here could be applied to other immunoconjugates for targeted therapy of a broad spectru
65  of targeted amphipathic fusion peptides and immunoconjugates for the ablation of prostate cancer cel
66  per L) could receive an initial dose of the immunoconjugate gemtuzumab ozogamicin (6 mg/m(2) intrave
67                      Such agents include the immunoconjugate gemtuzumab ozogamicin, multidrug resista
68 unization with the second-generation cocaine immunoconjugate GND-keyhole limpet hemocyanin (KLH) or w
69                           The IC(50)s of the immunoconjugate H-GA were 10-200-fold lower than that of
70                                    Unlabeled immunoconjugates had no effect on tumor growth.
71                Our results show that (1) the immunoconjugate has B-cell-specific in vitro and in vivo
72                                   This novel immunoconjugate has shown cytotoxic anti-prostate cancer
73    Radioimmunotherapy (RIT) with 90Y-labeled immunoconjugates has shown promise in clinical trials.
74                                      Several immunoconjugates have demonstrated impressive antigen-sp
75 reviously that an interferon (IFN)-MAb (1:1) immunoconjugate (IC) enhances tumor uptake by a factor o
76      A pretreatment with a single dose of an immunoconjugate (IC) that promises to enhance tumor upta
77 ules and anti-LFA-1-Ricin and anti-Iak-Ricin immunoconjugates (IC) were prepared and administered in
78                The efficacy and safety of an immunoconjugate (icon) molecule, composed of a mutated m
79                                              Immunoconjugates (ICs) consist of a cytotoxic effector c
80 ls and can be used as a target for cytotoxic immunoconjugates (ICs), in which cell-killing moieties,
81 t further broad clinical development of this immunoconjugate in CanAg-expressing tumors.
82 ng the rationale for clinical trials of this immunoconjugate in MM.
83                               The bloodborne immunoconjugates induce a cytolytic immune response agai
84                                Lym-1-21T-BAD immunoconjugate intermediate was prepared according to o
85                                          The immunoconjugate is composed of self-quenching, near-infr
86  in pediatric patients also suggest that the immunoconjugate is reasonably well tolerated.
87  Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjugate, is a re-emerging therapy for acute myel
88 nical studies using the (111)In radiolabeled immunoconjugate, MAb 7E11-C5.3-GYK-DTPA (capromab pendet
89                           Cytotoxic anti-HIV immunoconjugates may have greatest utility as part of an
90 erapy with a HER50 and HER66 photosensitizer immunoconjugate mixture was significantly more effective
91                                          The immunoconjugate molecule (Icon), which binds with high a
92 e treatment involves systemic delivery of an immunoconjugate molecule composed of a tumor-targeting d
93                                              Immunoconjugates--monoclonal antibodies (mAbs) coupled t
94          Here we describe targeted nanoscale immunoconjugates (NICs) on natural biopolymer scaffold,
95                    Gemtuzumab ozogamicin, an immunoconjugate of an anti-CD33 antibody linked to calic
96               Gemtuzumab ozogamicin (GO), an immunoconjugate of an anti-CD33 antibody that facilitate
97  describe the preclinical profile of another immunoconjugate of CalichDMH, CMC-544, targeted to CD22
98 tuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-gamma-calicheamicin dimethyl
99                                N901-bR is an immunoconjugate of N901 antibody with blocked ricin (bR)
100 model of human colorectal carcinoma using an immunoconjugate of the huA33 antibody modified with TCO
101          Antibody-targeted chemotherapy with immunoconjugates of calicheamicin, exemplified by gemtuz
102                    Furthermore, SC-delivered immunoconjugates of ENb and TRAIL target a wide spectrum
103 ab-PEG24-EGF at the NOAEL, or with unlabeled immunoconjugates or normal saline.
104 ype-specific anti-Ia mAb, haplotype-specific immunoconjugates, or mAb directed against graft APC, adh
105 r-killing power of toxic effector molecules, immunoconjugates permit sensitive discrimination between
106 vent spurs antibody production against these immunoconjugates, possibly leading to drug sequestration
107                    Preclinical studies using immunoconjugates prepared with toxins, drugs, or other a
108                                          The immunoconjugate preserved both antibody specificity and
109                             Splenocytes from immunoconjugate pretreated donors inhibited the mixed ly
110                   However, reported 90Y-DOTA immunoconjugate product yields have been typically only
111                                          The immunoconjugate product, 2IT-BAD-Lym-1, was labeled in e
112 as been eliminated or greatly reduced in the immunoconjugate products.
113      The specificity of antibodies have made immunoconjugates promising vectors for the delivery of r
114 rapy with a single anti-HER2 photosensitizer immunoconjugate, provided photosensitizer immunoconjugat
115 e of radiation-induced damage of 90Y-labeled immunoconjugate radiopharmaceuticals during preparation
116 ies (ENb) and imageable and proapoptotic ENb immunoconjugates released from stem cells (SC) to ultima
117             Several challenges in optimizing immunoconjugates remain, however, including poor intratu
118 otic/necrotic death in cells, treatment with immunoconjugates resulted in apoptotic death.
119 cination of GIX(+) mice with six unique METH immunoconjugates resulted in high antibody titers for th
120 r alone or together with the single-chain Fv immunoconjugate, resulted in growth inhibition and regre
121 g properties and rapid systemic clearance of immunoconjugates should lead to the design of effective
122 mor barrier and an (89)Zr-labeled pritumumab immunoconjugate showed the antibody specifically targete
123                                 The purified immunoconjugates showed similar binding specificity as d
124 mediated effector mechanisms or as cytotoxic immunoconjugates, such as immunotoxins (ITs).
125                                         BR96 immunoconjugates synthesized from methoxytriethylene gly
126                   These results show that an immunoconjugate targeted to CD33 can selectively ablate
127                                    Cytotoxic immunoconjugates targeted to HIV antigens on the cell su
128        Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, sho
129             The assay involves a recombinant immunoconjugate, termed Malibu-Glo reagent, comprising a
130 eparately or together with a single-chain Fv immunoconjugate that binds to the tumor cells, can inhib
131 CD19 for immunotoxins and probably for other immunoconjugates that act inside cells.
132                          We have synthesized immunoconjugates that induce an effective immune respons
133      C242-DM1 represents a new generation of immunoconjugates that may yet fulfill the promise of eff
134        Gemtuzumab ozogamicin (GO) is a novel immunoconjugate therapy for acute myeloid leukemia (AML)
135 Tat (GRKKRRQRRRPPQGYG) was also added to the immunoconjugate to aid nuclear translocation.
136                Because the binding of a fVII immunoconjugate to TF might cause disseminated intravasc
137 oved yields are needed for RIT with 90Y-DOTA immunoconjugates to be practical.
138  for the first time the use of micromagnetic immunoconjugates to establish a direct competitive assay
139 eloped fluorophore- and radioisotope-labeled immunoconjugates to target a DDR signaling protein, phos
140 se is the delivery of enough photosensitizer immunoconjugates to target cells.
141 tope HER2 targeting to boost photosensitizer immunoconjugate uptake as a way of enhancing photoimmuno
142 emtuzumab ozogamicin (GO; Mylotarg), a novel immunoconjugate used for treatment of acute myeloid leuk
143             At equimolar concentrations, the immunoconjugate was 8 times more cytotoxic against two c
144                                          The immunoconjugate was characterized using flow cytometry,
145                                The resulting immunoconjugate was labeled with [(227)Th]Th(IV) (pH 5.5
146 cell adhesion molecule (EpCAM) targeting MMC-immunoconjugate was prepared and dual-labeled with (64)C
147          The immunoreactivity of 90Y-labeled immunoconjugates was 100%+/-11%.
148         To develop effective taxane-antibody immunoconjugates, we have prepared a series of modified
149        The tumor-effective half-lives of the immunoconjugates were 39 hr for indium and 46 hr for ytt
150                   Indium-111-IgM and 90Y-IgM immunoconjugates were compared in nude mice at 2, 24, 72
151                                        These immunoconjugates were conjugated with DOTA and radiolabe
152                    Anti-HER2 photosensitizer immunoconjugates were constructed from two monoclonal an
153 ulfanyl(alkanoyl) groups for taxoid-antibody immunoconjugates were designed, synthesized and their ac
154                                          The immunoconjugates were encoded as secreted molecules in a
155                              Photosensitizer immunoconjugates were labeled instead with a promising a
156                                        These immunoconjugates were labeled with [(89)Zr]Zr(4+), and t
157         On a per mole basis, photosensitizer immunoconjugates were less phototoxic than free PPa, but
158 hototoxic than free PPa, but photosensitizer immunoconjugates were selective for target cells whereas
159                         High mole ratio BR96 immunoconjugates were synthesized using branched peptide
160                Furthermore, we labeled these immunoconjugates with (89)Zr and explored their biodistr
161 thesized a series of desferrioxamine-bearing immunoconjugates with differing glycosylation states and
162 conjugates (ADCs) represent a novel class of immunoconjugates with growing therapeutic relevance, sin
163                                 We generated immunoconjugates with low (nimotuzumab-PEG(6)-DM1-Low) a
164                              Photosensitizer immunoconjugates with PPa/mAb molar ratios up to approxi
165 riginally developed to label photosensitizer immunoconjugates with the photosensitizer, benzoporphyri

 
Page Top